No PRAME encore for Immatics
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
BioNTech puts a ring on Biotheus
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
Triple meeting 2024 – Zai Lab impresses in small cell
ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.
Carvykti takes off
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
